• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    安泰人壽

    安泰人壽

    Aetna
    企业
    325论文总数
    9,202引用总数

    论文量&引用量时间轴

    机构学者

    论文(325)

    年份
    起
    –
    止
    排序
    1AMCP Market Insights: Getting to the Heart of Hard-to-control Hypertension in Managed Care
    Bridget Flavin, Denise Wolff, Gaurang Gandhi, Hiva Pourarsalan,Florian Rader, Terry Richardson, Michael Shannon, Stephanie Spence, Susan Wescott

    Hard-to-control hypertension, comprising uncontrolled and resistant hypertension, is highly prevalent, meaning many patients with hypertension remain at risk of adverse outcomes despite treatment. To discuss the role of managed care in addressing hard-to-control hypertension, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in November 2025. This article provides a qualitative summary of the panel discussion. Key insights were that despite multiple effective, low-cost pharmacotherapy options, a significant proportion of patients have blood pressure above recommended goals because of confounding factors at both the micro and macro levels; and managed care-specific challenges in hard-to-control hypertension include competing organizational priorities, data gaps, and lack of integration of existing resources. Opportunities to advance care in hard-to-control hypertension include focusing on prevention and providing additional patient and clinician support such as with education and enhancing use of digital technologies. Other insights were that top payer priorities in hypertension include reducing cardiovascular events and other complications and meeting quality goals, and that current clinical guidelines and provider input are important elements of payer decision-making. These findings can support informed clinical and coverage decisions, can offer practical actions for payers, and may inform future work.

    2026Journal of managed care & specialty pharmacy(2026)
    引用
    AI阅读
    加入学术空间
    2CO197 COMPARING HEALTH CARE UTILIZATION AND EXPENDITURES BETWEEN VALUE-BASED PAYMENT AND NON-VALUE-BASED PAYMENT IN MEDICARE ADVANTAGE
    Eleanor Beltz, Wei Xin, Amanda Zaleski, Elyse Pegler, Kelly Thomas Craig
    2026VALUE IN HEALTH(2026)
    引用
    AI阅读
    加入学术空间
    3Early Technology Review During Prototype Development and at Proof of Concept: the Case for Developing a Sequential Versus a Single-Stage Approach to Early Evidence Development for Health Technologies
    Leslie Levin, Robert S McDonough, Martin Cheatle,Haytham Kaafarani, Serge Korjian,Richard E Kuntz

    The effect of Early Technology Review (ETR) through early engagement with multiple stakeholders on strategic development for technologies at prototype development and proof of concept was examined through two generic case studies of relevant outcomes. In both examples, advice to companies could have significantly changed strategic direction to become more relevant to payers and clinical experts. In one instance, the advice was followed and resulted in an expedited first-in-human study and was considered for a second ETR to inform the proof-of-concept study. In the second example, it was reported that changes in strategic direction were being considered.These reports provide descriptive accounts of very early applications of the ETR process that now spans the entire preclinical trajectory. Had the second case study at proof of concept been able to benefit from this approach at the point of prototype development, it could have avoided the costs and research through earlier advice. This begs the question whether a sequential iterative approach to evidentiary multiple stakeholder advice across the technology life cycle may reduce risk and cost while benefitting from efficiencies of applying adaptive design.

    2026International journal of technology assessment in health care(2026)
    引用
    AI阅读
    加入学术空间
    4National Comprehensive Cancer Network Guideline Compliance in an Oncology Value-Based Care Program Serving Medicare Members.
    Shirisha Reddy, Anthony Larrarte, Robert Cullum Jr, Kevin Hastings, Brooke Byrd, Rogelio Alberto Brito, Josh Eaves, Kiana Mehring, Lucio Gordon

    e23219 Background: Value-based care (VBC) focuses on improving patient health outcomes while reducing the overall cost of healthcare. The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide evidence-based and consensus-driven recommendations for the management of cancer. These guidelines aim to ensure that patients receive the most effective preventive, diagnostic, treatment, and supportive services to achieve optimal outcomes. They are considered the standard for clinical direction and policy in cancer care and are regularly updated. The NCCN Guidelines are designed to assist healthcare professionals, patients, and their families in making informed decisions and improving patient care and outcomes. 1 While studies have shown that compliance to NCCN guidelines improves survival, little information exists regarding the impact of compliance in VBC arrangements. This study aimed to evaluate compliance to NCCN regimen guidelines in Medicare members being treated for cancer under a VBC arrangement. Methods: This is a cohort study of individuals receiving care, in a single state, enrolled in a VBC contract within a large national insurer from January 18, 2024 to October 28, 2024. Medicare members with bladder, colon, lung, breast, hepatocellular, rectal, pancreatic, kidney, biliary tract and prostate cancer with at least one oncology claim within the measurement time period were included. NCCN compliance was a quality measure of the VBC, was defined using pharmacy and medical claims and deemed as concordant if the entire prescribed treatment regimen matched an NCCN recommended regimen (Level 1 and 2a); members not receiving an NCCN recommended regimen were deemed to be non-concordant. Results: This study included 332 patients, the mean [SD] age was 73.7 [6.9] years with 183 [55.1%] members identified as female. Avg Age Female [73.7] while Male was [73.8]. The total population captured through the automated prior authorization platform yielded 95.7% NCCN compliance. Conclusions: In this study, individuals receiving chemotherapy participating in a shared savings VBC demonstrated 95.7% compliance to NCCN guidelines. Embedding NCCN regimen compliance into VBC quality measures, coupled with online, real-time compliance assistance helps drive optimal NCCN compliance rates in Medicare patients and, in turn, improve clinical outcomes for patients. References #1: https://www.nccn.org/guidelines/guidelines-process/about-nccn-clinical-practice-guidelines#:~:text = The%20NCCN%20Guidelines%C2%AE%20are,in%20any%20area%20of%20medicine .

    2025JOURNAL OF CLINICAL ONCOLOGY(2025)
    引用
    AI阅读
    加入学术空间
    5Clinical Use of Artificial Intelligence Requires AI-capable Organizations
    Laurie Lovett Novak,Regina G. Russell,Kim Garvey,Mehool Patel,Kelly Jean Thomas Craig,Jane Snowdon,Bonnie Miller

    Abstract Artificial intelligence-based algorithms are being widely implemented in health care, even as evidence is emerging of bias in their design, problems with implementation, and potential harm to patients. To achieve the promise of using of AI-based tools to improve health, healthcare organizations will need to be AI-capable, with internal and external systems functioning in tandem to ensure the safe, ethical, and effective use of AI-based tools. Ideas are starting to emerge about the organizational routines, competencies, resources, and infrastructures that will be required for safe and effective deployment of AI in health care, but there has been little empirical research. Infrastructures that provide legal and regulatory guidance for managers, clinician competencies for the safe and effective use of AI-based tools, and learner-centric resources such as clear AI documentation and local health ecosystem impact reviews can help drive continuous improvement.

    2023JAMIA OPEN(2023)引用:26
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 325 篇论文

    合作机构(100)

    哈佛大学合作论文 29
    布莱根妇女医院合作论文 22
    美国食品药品管理局合作论文 16
    哈佛医学院合作论文 15
    哈佛朝圣者健康中心护理合作论文 11
    Centro de Epilepsia y Neurocirugía Funcional合作论文 7
    杜克大学合作论文 6
    CVS Health合作论文 5
    范德比尔特大学合作论文 5
    斯坦福大学合作论文 5

    机构统计